NASDAQ · IPSC
Century Therapeutics, Inc.
$1.46-$0.04 (-2.67%)
Century Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.97% below the high.
Loading market information…
NASDAQ · SRTS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Sensus Healthcare, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.54% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sensus Healthcare, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the SRT-100, a photon X-ray system for low-energy superficial radiotherapy. This device presents a non-surgical alternative for patients dealing with non-melanoma skin cancers, including basal cell and squamous cell carcinomas, alongside other dermatological issues like keloids. Another key offering is the SRT-100 Vision, which incorporates a specialized SRT treatment planning application. This application seamlessly integrates an embedded high-frequency ultrasound imaging module, tools for volumetric tumor analysis, beam margin delineation, and dosimetry parameter configuration. In addition, Sensus Healthcare provides the SRT-100 Plus, the Sentinel service program to ensure system protection for its clients, and options for in-office laser rentals. They also supply various consumable items, such as replacement lead shielding, disposable radiation safety gear like aprons and eye shields, ultrasound probe film, and single-use applicator tips designed to treat lesions of different sizes and on various body areas. Founded in 2010, Sensus Healthcare, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 | Feb 5, 2025 | $0.09-10.0% vs estimate | $13.07M+105.61% vs estimate |
|---|
| Q3 2024 | Nov 14, 2024 | $0.07+799.74% vs estimate | $8.84M+49.93% vs estimate |
|---|
THE ANALYST VIEW
9 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $4.75.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1.46-$0.04 (-2.67%)
Century Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.97% below the high.
$1.57+$0.01 (+0.64%)
Spectral AI, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.14% below the high.
$0.92-$0.06 (-5.74%)
TELA Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.67% below the high.
$1.18-$0.01 (-0.84%)
PetMed Express, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.22% below the high.
$0.88+$0.05 (+5.73%)
Karyopharm Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.99% below the high.
$4.40-$0.84 (-16.03%)
Cytosorbents Corporation’s quoted price sits in the lower half of its reported 52-week range, 74.12% below the high.
$0.22+$0.00 (+0.88%)
Senti Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.47% below the high.
$0.19-$0.06 (-24.8%)
Baird Medical Investment Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 94.92% below the high.
